3 no longer available, 1 enrolling by invitation, 1 terminated. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Enrolling by invitation 1 |
| Phase 2 | 1 | Terminated 1 |
Follow HBOC-201: new trials by email Literature Review of HBOC-201 trials Research Report on HBOC-201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia HBOC-201 - Anemia | Not applicable | Enrolling by invitation | Englewood Hospital and Medical Center | 50 | 2013-10-01 | 2025-04-13 |
| Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia Hemoglobin glutamer 250 - bovine, 6% Hydroxyethylstarch - Peripheral Vascular Disease | Phase 2 | Terminated | Biopure Corporation | 16 | 2006-05-01 | 2008-05-16 |
| Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia HBOC-201 - Anemia Severe | No longer available | Michael Boisen | 2026-07-20 | |||
| Expanded Access Protocol Using HBOC-201 HBOC-201 - Anemia | No longer available | Johns Hopkins University | 2025-10-23 | |||
| HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option HBOC-201 - Anemia | No longer available | Mauricio Lynn | 2024-12-20 |
Anemia (3) · Chronic Limb-Threatening Ischemia (1) · Hematologic Diseases (1) · Peripheral Vascular Diseases (1)
Biopure Corporation (1) · Englewood Hospital and Medical Center (1) · Johns Hopkins University (1) · Mauricio Lynn (1) · Michael Boisen (1)
United States (4) · South Africa (1) · United Kingdom (1)
A. Gerson Greenburg, MD, Ph.D. (1) · Carmine Gianatiempo, MD (1) · Mauricio Lynn (1) · Steven M Frank, MD (1)